Advantages and limitations of shot-gun proteomic analyses on Arabidopsis plants with altered MAPK signaling.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Proteomic Analysis of ArabidopsisFrontiers in plant science · 2019
   Article
2. Proteomic and Metabolomic Profiling ofFrontiers in microbiology · 2019
   Article
3. Sufentanil protects the rat myocardium against ischemia-reperfusion injury via activation of the ERK1/2 pathway.Cytotechnology · 2018
   Article
4. Comparative proteomic study of Arabidopsis mutants mpk4 and mpk6.Scientific reports · 2016
   Article
5. Genome-Wide Identification, Evolution, and Co-expression Network Analysis of Mitogen-Activated Protein Kinase Kinase Kinases inFrontiers in plant science · 2016
   Article
6. Cellular reprogramming through mitogen-activated protein kinases.Frontiers in plant science · 2015
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as